Product
Berzosertib
Aliases
2-Pyrazinamine, 3-(3-(4-((Methylamino)methyl)phenyl)-5-isoxazolyl)-5-(4-((1-methylethyl)sulfonyl)phenyl)-, M6620, M 6620, VX970 (2 other aliases)
13 clinical trials
54 indications
Indication
Small Cell Lung CancerIndication
Ovarian Serous TumorIndication
Recurrent Fallopian Tube CarcinomaIndication
Recurrent Ovarian CarcinomaIndication
Recurrent Primary Peritoneal CarcinomaIndication
Colorectal cancerIndication
Small Cell Lung CarcinomaIndication
Metastatic Malignant Solid NeoplasmIndication
Pancreatic CancerIndication
Colorectal CancerIndication
Lung Small Cell CarcinomaIndication
Malignant Solid NeoplasmIndication
Stage III Lung Cancer AJCC v8Indication
Stage III Pancreatic CancerIndication
Colorectal Cancer stage IV AJCC v8Indication
Stage IV Lung CancerIndication
Unresectable Pancreatic CarcinomaIndication
small cell lung cancerIndication
Advanced Solid TumorIndication
Neuroendocrine CancersIndication
Castration-Resistant Prostate CarcinomaIndication
Prostate CancerIndication
Extensive-stage small cell lung cancerIndication
Limited-Stage Lung Small Cell CarcinomaIndication
Recurrent Lung Small Cell CarcinomaIndication
Fallopian Tube CarcinomaIndication
Ovarian CancerIndication
Primary Peritoneal CarcinomaIndication
Ovarian Endometrioid TumorIndication
Ovarian High Grade Serous AdenocarcinomaIndication
Platinum-Sensitive Ovarian CarcinomaIndication
Fallopian Tube CancerIndication
Metastatic Lung Neuroendocrine NeoplasmIndication
Metastatic Lung Non-Small Cell CarcinomaIndication
Brain MetastasesIndication
Lung Cancer Stage IVA AJCC v8Indication
Lung CancerIndication
Lung Non-Small Cell Squamous CarcinomaIndication
HRD CancerIndication
CancerIndication
Breast CarcinomaIndication
Breast CancerIndication
Triple-Negative Breast CarcinomaIndication
Stage III Gastric CancerIndication
Gastroesophageal Junction AdenocarcinomaIndication
Stage IV Gastric CancerIndication
Gastric AdenocarcinomaIndication
Gastric CancerClinical trial
A Phase II, Open-label, Single-arm Study of Berzosertib (M6620) in Combination With Topotecan in Participants With Relapsed Platinum-resistant Small-Cell Lung Cancer (DDRiver SCLC 250)Status: Completed, Estimated PCD: 2023-07-21
Clinical trial
Phase 2 Study of M6620 (VX-970) in Combination With Gemcitabine Versus Gemcitabine Alone in Subjects With Platinum-Resistant Recurrent Ovarian or Primary Peritoneal Fallopian Tube CancerStatus: Active (not recruiting), Estimated PCD: 2020-06-15
Clinical trial
Phase I Clinical Trial of M6620 (VX-970, Berzosertib) in Combination With the Topoisomerase I Inhibitor Irinotecan in Patients With Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2023-03-07
Clinical trial
A Phase I/II Trial of Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High Grade Neuroendocrine CancersStatus: Recruiting, Estimated PCD: 2026-08-01
Clinical trial
A Phase 2 Study of M6620 (VX-970, Berzosertib) in Combination With Carboplatin Compared With Docetaxel in Combination With Carboplatin in Metastatic Castration-Resistant Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
DNA Damage Repair (DDR) Inhibitor-Based Basket of Baskets Phase I/II Trial in Patients With Advanced Solid Tumors Harboring Aberrations in DDR Genes (D-BoB)Status: Active (not recruiting), Estimated PCD: 2024-09-11
Clinical trial
Randomized Phase II Trial of Topotecan Plus M6620 (VX-970, Berzosertib) vs. Topotecan Alone in Patients With Relapsed Small-Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2022-12-19
Clinical trial
Phase 1 Dose Escalation and Expansion Cohort of Carboplatin and Gemcitabine With or Without M6620 (VX-970) in First or Second Recurrence Platinum-Sensitive Epithelial Ovarian, Peritoneal, and Fallopian Tube CancerStatus: Active (not recruiting), Estimated PCD: 2024-11-30
Clinical trial
Phase 1 Trial to Determine the Recommended Phase 2 Dose (RP2D) of M6620 (VX-970, Berzosertib) When Combined With Whole Brain Radiotherapy (WBRT) in Patients With Brain Metastases From Lung CancerStatus: Active (not recruiting), Estimated PCD: 2021-08-23
Clinical trial
A Phase IB and Randomized Open-Label Phase II Study of Berzosertib (M6620, VX-970) in Combination With Carboplatin/Gemcitabine/Pembrolizumab in Patients With Chemotherapy-Naïve Advanced Non-Small Cell Lung Cancer of Squamous Cell HistologyStatus: Active (not recruiting), Estimated PCD: 2024-03-31
Clinical trial
A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP InhibitorsStatus: , Estimated PCD: 2026-03-01
Clinical trial
A Phase 1b Study of Berzosertib in Combination With Radiation Therapy to Overcome Therapeutic Resistance in Chemotherapy Resistant Triple Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast CancerStatus: Active (not recruiting), Estimated PCD: 2024-11-20
Clinical trial
A Phase 2 Single-Arm Study of M6620 in Combination With Irinotecan in Patients With Progressive TP53 Mutant Gastric and Gastro-Esophageal Junction CancerStatus: Active (not recruiting), Estimated PCD: 2024-07-01